Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotechnology company focused on mRNA cell therapies for autoimmune diseases, has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's management will engage in a fireside chat scheduled for Tuesday, April 8, 2025, at 2:15 p.m. ET. Investors and interested parties can access the live webcast through the Events section of Cartesian's website at www.cartesiantherapeutics.com. An archived replay will be available for a time after the event.
Cartesian Therapeutics (NASDAQ: RNAC), un'azienda biotecnologica in fase clinica focalizzata sulle terapie cellulari mRNA per le malattie autoimmuni, ha annunciato la sua prossima partecipazione alla 24ª Conferenza Virtuale Annuale di Needham sulla Salute.
La direzione dell'azienda parteciperà a una chiacchierata informale programmata per martedì 8 aprile 2025, alle 14:15 ET. Gli investitori e le parti interessate possono accedere alla diretta streaming attraverso la sezione Eventi del sito web di Cartesian all'indirizzo www.cartesiantherapeutics.com. Una registrazione dell'evento sarà disponibile per un certo periodo dopo la sua conclusione.
Cartesian Therapeutics (NASDAQ: RNAC), una empresa biotecnológica en etapa clínica centrada en terapias celulares de ARNm para enfermedades autoinmunes, ha anunciado su próxima participación en la 24ª Conferencia Virtual Anual de Salud de Needham.
La dirección de la empresa participará en una charla informal programada para el martes 8 de abril de 2025, a las 2:15 p.m. ET. Los inversores y partes interesadas pueden acceder a la transmisión en vivo a través de la sección de Eventos en el sitio web de Cartesian en www.cartesiantherapeutics.com. Una repetición archivada estará disponible por un tiempo después del evento.
Cartesian Therapeutics (NASDAQ: RNAC)는 자가면역 질환을 위한 mRNA 세포 치료에 중점을 둔 임상 단계 생명공학 회사로, 제24회 니드햄 연례 가상 헬스케어 컨퍼런스에 참석할 예정이라고 발표했습니다.
회사의 경영진은 2025년 4월 8일 화요일 오후 2시 15분 ET에 예정된 대화에 참여할 것입니다. 투자자와 관심 있는 분들은 www.cartesiantherapeutics.com의 이벤트 섹션을 통해 실시간 웹캐스트에 접속할 수 있습니다. 이벤트 후 일정 기간 동안 아카이브된 재생이 제공될 예정입니다.
Cartesian Therapeutics (NASDAQ: RNAC), une entreprise de biotechnologie en phase clinique axée sur les thérapies cellulaires à base d'ARNm pour les maladies auto-immunes, a annoncé sa prochaine participation à la 24e Conférence Virtuelle Annuelle de Needham sur la Santé.
La direction de l'entreprise participera à une discussion informelle prévue pour mardi 8 avril 2025, à 14h15 ET. Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct via la section Événements du site Web de Cartesian à l'adresse www.cartesiantherapeutics.com. Un enregistrement de l'événement sera disponible pendant un certain temps après sa conclusion.
Cartesian Therapeutics (NASDAQ: RNAC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf mRNA-Zelltherapien für Autoimmunerkrankungen spezialisiert hat, hat seine bevorstehende Teilnahme an der 24. jährlichen Needham virtuellen Gesundheitskonferenz angekündigt.
Das Management des Unternehmens wird an einem informellen Gespräch teilnehmen, das für Dienstag, den 8. April 2025, um 14:15 Uhr ET geplant ist. Investoren und Interessierte können über den Bereich Veranstaltungen auf der Website von Cartesian unter www.cartesiantherapeutics.com auf den Live-Webcast zugreifen. Eine archivierte Wiederholung wird für eine gewisse Zeit nach der Veranstaltung verfügbar sein.
- None.
- None.
FREDERICK, Md., April 01, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 2:15 p.m. ET.
A live webcast of the presentation and fireside chats is expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time.
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an mRNA CAR-T entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. A Phase 3 trial of Descartes-08 in patients with generalized myasthenia gravis has received written agreement from the FDA under the Special Protocol Assessment process. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.
Investor Contact
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com
Media Contact
David Rosen
Argot Partners
david.rosen@argotpartners.com
FAQ
When is Cartesian Therapeutics (RNAC) presenting at the Needham Healthcare Conference 2025?
How can investors watch Cartesian Therapeutics' (RNAC) Needham Conference presentation?
What is the main focus of Cartesian Therapeutics' (RNAC) research and development?
What type of event will RNAC participate in at the Needham Healthcare Conference?
